e-Drug3D

1292

IMATINIB


INN
IMATINIB

cas 152459-95-5
CLASS

ANTINEOPLASTIC AGENTS
PROTEIN TYROSINE KINASE INHIBITORS
TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML)

ROUTE (list)

ORAL

ATC code

L01EA01

PK parameters

F 98 PERCENT
Tmax 1.5 HOUR
VD 435 LITER
Cl 14 LITER / HOUR
PPB 95 PERCENT
t1/2 18 HOUR

Solubility

SOLUBLE IN AQUEOUS BUFFERS < PH 5.5 BUT IS VERY SLIGHTLY SOLUBLE TO INSOLUBLE IN NEUTRAL OR ALKALINE AQUEOUS BUFFERS


Target

TARGET BCR-ABL TYROSINE KINASE
PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGF)
STEM CELL FACTOR (SCF)
C-KIT

PDB
3MSS (ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE)

Ligand code = STI (link to the list of PDB complexes)

Download experimental 3D coordinates of STI with added hydrogens

DrugCentral

Platelet-derived growth factor receptor beta UNIPROT P09619 PDGFRB

Tyrosine-protein kinase ABL1 UNIPROT P00519 ABL1

Download SDF file 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide

Formula:
C29H31N7O

Calculated chemical properties:

MW 493.61
NB_atoms 37
XLogP 4.59
PSA 75.246
NB_HD 2
NB_HA 8
fsp3 0.24
Lipinski(0=no;1=yes) 1

FDA
NDA 021335 (label) INN (IMATINIB MESYLATE) GLEEVEC (NOVARTIS) APPROVAL= AP YEAR= 2001 NEWMOLECULARENTITY DISCONTINUED
NDA 021588 (label) INN (IMATINIB MESYLATE) GLEEVEC (NOVARTIS) APPROVAL= AP YEAR= 2003
NDA 078340 (pdf not found) INN (IMATINIB MESYLATE) IMATINIB MESYLATE (SUN PHARM) APPROVAL= AP YEAR= 2015 DISCONTINUED
NDA 079179 (pdf not found) INN (IMATINIB MESYLATE) IMATINIB MESYLATE (APOTEX) APPROVAL= AP YEAR= 2016
NDA 204285 (pdf not found) INN (IMATINIB MESYLATE) IMATINIB MESYLATE (TEVA PHARMS USA) APPROVAL= AP YEAR= 2016
NDA 204644 (pdf not found) INN (IMATINIB MESYLATE) IMATINIB MESYLATE (MYLAN) APPROVAL= AP YEAR= 2017
NDA 206547 (pdf not found) INN (IMATINIB MESYLATE) IMATINIB MESYLATE (DR REDDYS) APPROVAL= AP YEAR= 2018
NDA 207586 (pdf not found) INN (IMATINIB MESYLATE) IMATINIB MESYLATE (HIKMA) APPROVAL= AP YEAR= 2018 DISCONTINUED
NDA 205990 (pdf not found) INN (IMATINIB MESYLATE) IMATINIB MESYLATE (NOVITIUM PHARMA) APPROVAL= AP YEAR= 2019 DISCONTINUED
NDA 207495 (pdf not found) INN (IMATINIB MESYLATE) IMATINIB MESYLATE (AMNEAL PHARMS) APPROVAL= AP YEAR= 2019 DISCONTINUED
NDA 207818 (pdf not found) INN (IMATINIB MESYLATE) IMATINIB MESYLATE (NATCO PHARMA LTD) APPROVAL= AP YEAR= 2019
NDA 208302 (pdf not found) INN (IMATINIB MESYLATE) IMATINIB MESYLATE (SHILPA) APPROVAL= AP YEAR= 2019
NDA 208429 (pdf not found) INN (IMATINIB MESYLATE) IMATINIB MESYLATE (CHARTWELL RX) APPROVAL= AP YEAR= 2019
NDA 210658 (pdf not found) INN (IMATINIB MESYLATE) IMATINIB MESYLATE (ZYDUS PHARMS) APPROVAL= AP YEAR= 2020
NDA 212773 (pdf not found) INN (IMATINIB MESYLATE) IMATINIB MESYLATE (EUGIA PHARMA) APPROVAL= AP YEAR= 2020
NDA 212135 (pdf not found) INN (IMATINIB MESYLATE) IMATINIB MESYLATE (QILU PHARM HAINAN) APPROVAL= AP YEAR= 2022
NDA 219097 (label) INN (IMATINIB MESYLATE) IMKELDI (SHORLA ONCOLOGY) APPROVAL= AP YEAR= 2024
NDA 212193 (pdf not found) INN (IMATINIB MESYLATE) IMATINIB MESYLATE (CSPC OUYI) APPROVAL= AP YEAR= 2025
NDA 212975 (pdf not found) INN (IMATINIB MESYLATE) IMATINIB MESYLATE (HETERO LABS LTD V) APPROVAL= AP YEAR= 2025

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL